NCT04645212View on ClinicalTrials.gov

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, not recruitingOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

ADVM-022

Long term follow-up of subjects that received ADVM-022

Trial Locations (9)

19107

Adverum Clinical Site, Philadelphia

33064

Adverum Clinical Site, Deerfield Beach

37203

Adverum Clinical Site, Nashville

77384

Adverum Clinical Site, The Woodlands

77401

Adverum Clinical Site, Bellaire

80228

Adverum Clinical Site, Lakewood

89502

Adverum Clinical Site, Reno

90211

Adverum Clinical Site, Beverly Hills

93309

Adverum Clinical Site, Bakersfield

Sponsors
All Listed Sponsors
lead

Adverum Biotechnologies, Inc.

INDUSTRY